Debiopharm InternationalLausanne, Vaud, Switzerland
Disclosure(s): Debiopharm International: Salary
107 - Results from A Phase 2 Clinical Trial for Treatment of Bone And Joint Infections with Afabicin, A First-in-Class Selective Anti-Staphylococcal Antibiotic
Thursday, October 17, 202412:35 PM – 12:40 PM US PT